mAbs

Top Research Topics at mAbs?

The aim of mAbs is to expand the discussion of research in Antibody, Monoclonal antibody, Molecular biology, Immunology and Biochemistry. While the primary focus in it is Antibody, it also dissects topics surrounding In vivo and In vitro as a whole. MAbs addresses concerns in Monoclonal antibody which are intertwined with other disciplines, such as Pharmacokinetics, Pharmacology, Recombinant DNA, Virology and Chromatography.

More specifically, the research on Chromatography in mAbs is related to Mass spectrometry. The concepts on Molecular biology presented in it can also apply to other research fields, including Immunoglobulin G, Neonatal Fc receptor, Immunoglobulin light chain, Cell biology and Phage display. It dives deep in exploring the relationship between the study of Immunology and Cancer research.

The works on Biochemistry deal in particular with Glycosylation. It investigates Glycosylation research which frequently intersects with Glycan. The work on Epitope presented in it focuses on Epitope mapping in particular.

• Antibody (51.44%)
• Monoclonal antibody (41.62%)
• Molecular biology (20.09%)

What are the most cited papers published in the journal?

• The therapeutic monoclonal antibody market (846 citations)
• The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions (487 citations)
• Industrialization of mAb production technology: The bioprocessing industry at a crossroads (483 citations)

Research areas of the most cited articles at mAbs:

The journal publications investigate studies in Antibody, Monoclonal antibody, Immunology, Molecular biology and Biochemistry. While Antibody is the focus of the most cited articles, it also provides insights into the studies of Receptor, In vivo, Pharmacology and Antigen. The most cited articles address concerns in Monoclonal antibody which are intertwined with other disciplines, such as Epitope, Chromatography, Immunogenicity and Virology.

What topics the last edition of the journal is best known for?

• Gene
• Enzyme
• Antibody

The previous edition focused in particular on these issues:

MAbs aims to foster the development of research in Antibody, Monoclonal antibody, Computational biology, Epitope and Cancer research. The journal explores topics in Antibody which can be helpful for research in disciplines like In vivo, Drug, Antigen and Virology. Nuclear magnetic resonance spectroscopy, Pharmacokinetics, Biochemistry and Drug development are some topics wherein Monoclonal antibody research discussed in the journal have an impact.

MAbs holds forums on Computational biology that merges themes from other disciplines such as In silico, Selection (genetic algorithm), DNA sequencing and Drug discovery. While mAbs focused on Epitope, it was also able to explore topics like Immunoglobulin light chain and breakpoint cluster region. The journal deals with Cancer research in conjunction with other fields like

• Immunotherapy that connect with fields like CTLA-4,
• Bispecific antibody, which have a strong connection to T cell..

The most cited articles from the last journal are:

• Antibodies to watch in 2021. (38 citations)
• 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro . (14 citations)
• Coming together at the hinges: Therapeutic prospects of IgG3 (5 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in mAbs (based on the number of publications) are:

• Janice M. Reichert (56 papers) published 1 paper at the last edition the same number as at the previous edition,
• Alain Beck (32 papers) absent at the last edition,
• Dimiter S. Dimitrov (18 papers) absent at the last edition,
• Herren Wu (16 papers) absent at the last edition,
• Hervé Watier (16 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in mAbs (based on the number of publications) are:

• Genentech (108 papers) published 5 papers at the last edition, 3 less than at the previous edition,
• Hoffmann-La Roche (65 papers) published 7 papers at the last edition, 1 less than at the previous edition,
• MedImmune (57 papers) absent at the last edition,
• Pfizer (57 papers) published 5 papers at the last edition, 3 more than at the previous edition,
• Amgen (42 papers) published 4 papers at the last edition, 1 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 9.76% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 41.89% were posted by at least one author from the top 10 institutions publishing in the journal. Another 13.51% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 21.62% of all publications and 22.97% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.